YenZym Antibodies
Private Company
Total funding raised: $2.3M
Overview
YenZym Antibodies operates as a specialized contract research organization (CRO) providing custom antibody generation services to the global life sciences research community. The company's key differentiator is its deep expertise in designing antigens for difficult-to-target proteins, such as GPCRs and ion channels, and its focus on producing antibodies specific to a wide array of post-translational modifications. Led by an experienced immunologist, Dr. Yen, the firm leverages over 25 years of cumulative experience to offer tailored immunization regimens, positioning itself as a problem-solving partner for academic and industrial researchers. Its business model is entirely service-based, generating revenue from project fees for custom antibody development.
Technology Platform
Expert-led methodology for custom antigen design and tailored immunization regimens, specializing in antibodies against post-translational modifications (PTMs) and difficult protein targets like GPCRs.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
YenZym competes in the fragmented custom antibody services market against large reagent suppliers (e.g., Thermo Fisher, Abcam), university core facilities, and other specialized CROs. Its differentiation lies in its deep focus on challenging PTM and membrane protein targets and its high-touch, expert-led project design, rather than competing on high-throughput or low-cost production.